Outputs (113)

Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins? (2016)
Journal Article
Toss, M. S., Pinder, S. E., Green, A. R., Thomas, J., Morgan, D. A., Robertson, J. F., Ellis, I. O., & Rakha, E. A. (2017). Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?. Histopathology, 70(5), 681-692. https://doi.org/10.1111/his.13116

The introduction of mammographic screening has resulted in a rise in the detection rate of ductal carcinoma in situ (DCIS), currently accounting for one‐fifth of screen‐detected breast cancers. Although 60–70% of DCIS are treated with breast‐conservi... Read More about Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?.

Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival (2016)
Journal Article
Xuan, P., Storr, S. J., Zhang, Y., Rakha, E., Green, A. R., Ellis, I. O., & Martin, S. G. (in press). Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. Apoptosis, https://doi.org/10.1007/s10495-016-1323-5

Impaired apoptosis is one of the hallmarks of cancer. Caspase-3 and -8 are key regulators of the apoptotic response and have been shown to interact with the calpain family, a group of cysteine proteases, during tumorigenesis. The current study sought... Read More about Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival.

Nostrin as a marker related to low grade and better prognosis in breast cancer (2016)
Presentation / Conference Contribution
Hamarsheh, S., Craze, M., Joseph, C., Provenzano, E., Russell, R., Caldas, C., Green, A., Rakha, E., Ellis, I., & Mukherjee, A. (2016, June). Nostrin as a marker related to low grade and better prognosis in breast cancer. Presented at Nottingham Pathology 2016: 9th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, Nottingham, UK

[This is an abstract on page S.20 of the proceedings.]

Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers (2016)
Journal Article
Ahmad, D. A. J., Negm, O. H., Layth Alabdullah, M., Mirza, S., Hamed, M. R., Band, V., Green, A. R., Ellis, I. O., & Rakha, E. (2016). Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers. Breast Cancer Research and Treatment, 159(3), 457-467. https://doi.org/10.1007/s10549-016-3967-9

Background Mitogen-activated protein kinases (MAPKs) are signalling transduction molecules that have different functions and diverse behaviour in cancer. In breast cancer, MAPK is related to oestrogen receptor (ER) and HER2.
Methods Protein express... Read More about Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers.

Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer (2016)
Journal Article
Besusparis, J., Plancoulaine, B., Rasmusson, A., Augulis, R., Green, A. R., Ellis, I. O., Laurinaviciene, A., Herlin, P., & Laurinavicius, A. (2016). Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer. Diagnostic Pathology, 11(1), Article 82. https://doi.org/10.1186/s13000-016-0525-z

Background: Gene expression studies have identified molecular subtypes of breast cancer with implications to chemotherapy recommendations. For distinction of these types, a combination of immunohistochemistry (IHC) markers, including proliferative ac... Read More about Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer.

Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein (2016)
Journal Article
Alshareeda, A., Negm, O. H., Aleskandarany, M. A., Green, A. R., Nolan, C., Tighe, P. J., Madhusudan, S., Ellis, I. O., & Rakha, E. (2016). Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein. Breast Cancer Research and Treatment, 159(1), 41-53. https://doi.org/10.1007/s10549-016-3915-8

Impaired DNA damage response (DDR) may play a fundamental role in the pathogenesis of breast cancer (BC). RAD51 is a key player in DNA double-strand break repair. In this study, we aimed to assess the biological and clinical significance of RAD51 exp... Read More about Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.

Overexpression of specific CD44 isoforms is associated with aggressive cell features in acquired endocrine resistance (2016)
Journal Article
Bellerby, R., Smith, C., Kyme, S., Gee, J., Günthert, U., Green, A., Rakha, E., Barrett-Lee, P., & Hiscox, S. (2016). Overexpression of specific CD44 isoforms is associated with aggressive cell features in acquired endocrine resistance. Frontiers in Oncology, 6, Article 145. https://doi.org/10.3389/fonc.2016.00145

While endocrine therapy is the mainstay of ER+ breast cancer, the clinical effectiveness of these agents is limited by the phenomenon of acquired resistance that is associated with disease relapse and poor prognosis. Our previous studies revealed tha... Read More about Overexpression of specific CD44 isoforms is associated with aggressive cell features in acquired endocrine resistance.

SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis (2016)
Journal Article
Abdel-Fatah, T. M., Agarwal, D., Liu, D.-X., Russell, R., Rueda, O. M., Liu, K., Xu, B., Moseley, P. M., Green, A. R., Pockley, A. G., Rees, R. C., Caldas, C., Ellis, I. O., Ball, G. R., & Chan, S. Y. (2016). SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis. Lancet Oncology, 17(7), 1004-1018. https://doi.org/10.1016/S1470-2045%2816%2900174-1

Background

Proliferation markers and profiles have been recommended for guiding the choice of systemic treatments for breast cancer. However, the best molecular marker or test to use has not yet been identified. We did this study to identify facto... Read More about SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes (2016)
Journal Article
Pereira, B., Chin, S.-F., Rueda, O. M., Vollan, H.-K. M., Provenzano, E., Bardwell, H. A., Pugh, M., Jones, L., Russell, R., Sammut, S.-J., Tsui, D. W., Liu, B., Dawson, S.-J., Abraham, J., Northen, H., Peden, J. F., Mukherjee, A., Turashvili, G., Green, A. R., McKinney, S., …Caldas, C. (in press). The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nature Communications, 7, Article 11479. https://doi.org/10.1038/ncomms11479

The genomic landscape of breast cancer is complex, and inter- and intra-tumour heterogeneity are important challenges in treating the disease. In this study, we sequence 173 genes in 2,433 primary breast tumours that have copy number aberration (CNA)... Read More about The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.

Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer (2016)
Journal Article
Green, A. R., Soria, D., Powe, D. G., Nolan, C. C., Aleskandarany, M. A., Szász, M., Tőkés, A., Ball, G., Garibaldi, J. M., Rakha, E., Kulka, J., & Ellis, I. O. (2016). Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer. Breast Cancer Research and Treatment, 157(1), 65-75. https://doi.org/10.1007/s10549-016-3804-1

The Nottingham prognostic index plus (NPI+) is based on the assessment of biological class combined with established clinicopathologic prognostic variables providing improved patient outcome stratification for breast cancer superior to the traditiona... Read More about Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.

Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers (2015)
Journal Article
Arora, A., Abdel-Fatah, T. M., Agarwal, D., Doherty, R., Croteau, D. L., Moseley, P. M., Hameed, K., Green, A., Aleskandarany, M. A., Patterson, K., Rakha, E. A., Ball, G., Chan, S. Y., Ellis, I. O., Bohr, V. A., Bryant, H. E., & Madhusudan, S. (2016). Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers. Carcinogenesis, 37(1), 63-71. https://doi.org/10.1093/carcin/bgv163

RECQL5 is a member of the RecQ family of DNA helicases and has key roles in homologous recombination, base excision repair, replication and transcription. The clinicopathological significance of RECQL5 expression in breast cancer is unknown. In this... Read More about Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers.

Nottingham Prognostic Index Plus: validation of a clinical decision making tool in breast cancer in an independent series (2015)
Journal Article
Green, A. R., Soria, D., Stephen, J., Powe, D. G., Nolan, C. C., Kunkler, I., Thomas, J., Kerr, G. R., Jack, W., Cameron, D., Piper, T., Ball, G. R., Garibaldi, J. M., Rakha, E., Bartlett, J. M., & Ellis, I. O. (2016). Nottingham Prognostic Index Plus: validation of a clinical decision making tool in breast cancer in an independent series. Journal of Pathology: Clinical Research, 2, https://doi.org/10.1002/cjp2.32

The Nottingham Prognostic Index Plus (NPI+)is a clinical decision making tool in breast cancer (BC) that aims to provide improved patient outcome stratification superior to the traditional NPI. This study aimed to validate the NPI+ in an independent... Read More about Nottingham Prognostic Index Plus: validation of a clinical decision making tool in breast cancer in an independent series.

Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma (2015)
Journal Article
Laurinavicius, A., Green, A. R., Laurinaviciene, A., Smailyte, G., Ostapenko, V., Meskauskas, R., & Ellis, I. O. (2015). Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma. Oncotarget, 6(38), 41134-41145. https://doi.org/10.18632/oncotarget.5838

Biological diversity of breast cancer presents challenges for personalized therapy and necessitates multiparametric approaches to understand and manage the disease. Multiple protein biomarkers tested by immunohistochemistry (IHC), followed by digital... Read More about Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma.

DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers (2015)
Journal Article
Abdel-Fatah, T. M., Arora, A., Moseley, P. M., Perry, C., Rakha, E. A., Green, A. R., Chan, S. Y., Ellis, I. O., & Madhusudan, S. (2015). DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers. Oncotarget, 6(26), 21964-21978. https://doi.org/10.18632/oncotarget.4157

Stratification of oestrogen receptor (ER) negative and triple negative breast cancers (TNBCs) is urgently needed. In the current study, a cohort of 880 ER- (including 635 TNBCs) was immuno-profiled for a panel of DNA repair proteins including: Pol β,... Read More about DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers.

KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer (2015)
Journal Article
Alshareeda, A., Negm, O., Green, A., Nolan, C., Tighe, P., Albarakati, N., Sultana, R., Madhusudan, S., Ellis, I., & Rakha, E. (2015). KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer. British Journal of Cancer, 112(12), 1929–1937. https://doi.org/10.1038/bjc.2015.165

Background: It is recognised that modulations of the nuclear import of macromolecules have a role in changing cellular phenotypes and carcinogenesis. We and others have noticed that aberrant subcellular localisation of DNA damage response (DDR) prote... Read More about KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer.

Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification (2015)
Journal Article
Aleskandarany, M. A., Soria, D., Green, A. R., Nolan, C., Diez-Rodriguez, M., Ellis, I. O., & Rakha, E. A. (2015). Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification. Breast Cancer Research and Treatment, 151(2), 325-333. https://doi.org/10.1007/s10549-015-3406-3

Accurate distant metastasis (DM) prediction is critical for risk stratification and effective treatment decisions in breast cancer (BC). Many prognostic markers/models based on tissue marker studies are continually emerging using conventional statist... Read More about Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification.

Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents (2015)
Journal Article
Ong, C. C., Gierke, S., Pitt, C., Sagolla, M., Cheng, C. K., Zhou, W., Jubb, A. M., Strickland, L., Schmidt, M., Duron, S. G., Campbell, D. A., Zheng, W., Dehdashti, S., Shen, M., Yang, N., Behnke, M. L., Huang, W., McKew, J. C., Chernoff, J., Forrest, W. F., …Hoeflich, K. P. (2015). Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Breast Cancer Research, 17(1), Article 59. https://doi.org/10.1186/s13058-015-0564-5

Introduction

Breast cancer, the most common cause of cancer-related deaths worldwide among women, is a molecularly and clinically heterogeneous disease. Extensive genetic and epigenetic profiling of breast tumors has recently revealed novel puta... Read More about Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.

FKBPL: a marker of good prognosis in breast cancer (2015)
Journal Article
Nelson, L., McKeen, H. D., Ellis, I., Rakha, E., Marshall, A., Mulrane, L., Starczynski, J., Storr, S. J., Lanigan, F., Byrne, C., Arthur, K., Hegarty, S., Abdunnabi Ali, A., Furlong, F., McCarthy, H. O., Ellis, I. O., Green, A. R., Rakha, E., Young, L., Kunkler, I., …Robson, T. (2015). FKBPL: a marker of good prognosis in breast cancer. Oncotarget, 6(14), 12209-12223. https://doi.org/10.18632/oncotarget.3528

FK506-binding protein-like (FKBPL) has established roles as an anti-tumor protein, with a therapeutic peptide based on this protein, ALM201, shortly entering phase I/II clinical trials. Here, we evaluated FKBPL’s prognostic ability in primary breast... Read More about FKBPL: a marker of good prognosis in breast cancer.

Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer (2015)
Journal Article
Abduljabbar, R., Al-Kaabi, M. M., Negm, O. H., Jerjees, D., Muftah, A. A., Mukherjee, A., Lai, C. F., Buluwela, L., Ali, S., Tighe, P. J., Green, A., Ellis, I., & Rakha, E. (2015). Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer. Breast Cancer Research and Treatment, 150(3), 511-522. https://doi.org/10.1007/s10549-015-3348-9

Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer (2015)
Journal Article
Abduljabbar, R., Negm, O. H., Lai, C.-F., Jerjees, D. A., Al-Kaabi, M., Hamed, M. R., Tighe, P. J., Buluwela, L., Mukherjee, A., Green, A. R., Ali, S., Rakha, E. A., & Ellis, I. O. (2015). Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer. Breast Cancer Research and Treatment, 150(2), 335-346. https://doi.org/10.1007/s10549-015-3335-1

The glucocorticoid receptor (GR) is a member of the nuclear receptor superfamily of transcription factors, which exerts anti-proliferative and anti-apoptotic activities. The GR is expressed in a large proportion of breast cancer (BC) although levels... Read More about Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer.